Home › Urothelial (Transitional Cell) Carcinoma › New Jersey › Clifton
Urothelial (Transitional Cell) Carcinoma clinical trials in Clifton, NJ
4 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Clifton (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #105, Hackensack · 7 mi away
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
RecruitingPhase 1/2
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · 7 mi away
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- John Theurer Cancer Center, Hackensack · 7 mi away
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RecruitingPhase 1/2
- John Theurer Cancer Center, Hackensack · 7 mi away
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Houston, TX19 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- Boston, MA11 studies
- San Antonio, TX11 studies
- Austin, TX10 studies
Other studies in Clifton
- Non-Small Cell Lung Cancer24 studies
- Cancer (all types)15 studies
- Multiple Myeloma14 studies
- Metastatic Cancer12 studies
- Acute Myeloid Leukemia12 studies
- Breast Cancer12 studies
- Prostate Cancer12 studies
- Ovarian Cancer11 studies
- Lung Cancer10 studies
- Colorectal Cancer8 studies
- Head and Neck Squamous Cell Carcinoma8 studies
- Endometrial Cancer8 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.